Doctor Reveals 1 Thing Kids Should 'Never' Do During Summer
However, while children are usually carefree, there are plenty of things their parents need to be concerned about when they're out playing, says Dr. Arun Chopra.
Chopra, a pediatric critical care physician, provided the New York Post with six safety tips for children this summer. The advice was related to staying cool, practicing water safety, avoiding bug bites and other important topics.
The one specific thing that Chopra said he "never let my kids do" is ride a bicycle, scooter, skateboard, ATV or any other device with wheels without the protection of a helmet.
"Head trauma is probably the most preventable serious injury that kids can get while playing," the doctor explained. "It really is an absolute requirement that they wear a helmet at all times."
Chopra added that he is concerned about brain damage and major head injuries, which is why he cautioned parents to be very wary of letting their kids ride one particular recreational vehicle.
"That's why I would be particularly cautious with ATVs. While they can be a lot of fun, they present significant risks," Chopra said. "First, they can go fast. Younger children can get thrown very easily, so helmets and seatbelts are imperative.
"They're also heavy and can crush a child if they roll over. Parents need to confirm that the machine is the right size and that operators know what they're doing. Alcohol should not be involved."
According to the Consumer Federation of America, there were 420 ATV fatalities in 2024. A large number--288 to be exact--of those deaths were suffered by the driver, with the passenger being killed 43 times and a bystander dying on three occasions.
Eighty-six ATV fatalities fall under the "unknown" or "other" categories. In total, 65 people between the ages of 0-15 were killed in ATV accidents, per the same report.
Doctor Reveals 1 Thing Kids Should 'Never' Do During Summer first appeared on Men's Journal on Jul 7, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
HCA Healthcare, Inc. (HCA): A Bull Case Theory
We came across a bullish thesis on HCA Healthcare, Inc. on Valueinvesting subreddit by DividendKing47. In this article, we will summarize the bulls' thesis on HCA. HCA Healthcare, Inc.'s share was trading at $334.32 as of July 25th. HCA's trailing and forward P/E were 14.04 and 13.32 respectively according to Yahoo Finance. A successful healthcare provider smiling confidently in a modern hospital facility. HCA Healthcare, the largest U.S. hospital operator, manages 190 hospitals nationwide and plans to expand further with $5.0–5.2 billion in 2025 capital expenditures to meet growing healthcare demand. Benefiting from a healthcare services industry projected to grow at a 4.9% CAGR through 2029, HCA targets raising its 27% market share to 29% by 2030. Its 2024 revenue reached $70.6 billion, with 2025 guidance of $74–76 billion, implying 6.2% growth at the midpoint, supported by $10.5 billion in free cash flow and a $140 billion enterprise value. Growth will be driven by facility upgrades, outpatient services expansion, and technological integration, including EHRs and AI-enabled diagnostics, enhancing efficiency and patient outcomes. HCA's strategic pivot toward outpatient care, alongside modernization of existing hospitals, positions it to capture an aging population's increasing needs while mitigating inpatient reimbursement risks. Consolidation trends favor HCA's acquisition-led growth, though competitive pressures from peers like Tenet Healthcare and Universal Health Services remain. A conservative DCF analysis, using a 9% WACC and 1.25% terminal growth, values the enterprise at $167 billion, with equity of $127.5 billion or $529.79 per share—representing 58.5% upside. Risks include regulatory changes, labor shortages, and public scrutiny that could pressure margins and volumes, as well as macroeconomic headwinds that may delay elective procedures. Nonetheless, HCA's scale, robust free cash generation, and focus on operational efficiency offer resilience. Even amid industry headwinds, its expansion strategy and strong positioning provide an attractive investment opportunity, with substantial upside potential underpinned by conservative growth assumptions and disciplined capital allocation. Previously, we covered a bullish thesis on Tenet Healthcare Corporation (THC) by BlackSwanInvestor in December 2024, which highlighted operational streamlining, debt reduction, and the rapid expansion of its high-margin Ambulatory Care segment. The company's stock price has appreciated by approximately 21.7% since our coverage, as the thesis played out. The thesis still stands as Ambulatory Care growth drives value creation. DividendKing47 shares a similar view but emphasizes HCA Healthcare's scale-driven expansion and capital allocation in the same healthcare services market. HCA Healthcare, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 74 hedge fund portfolios held HCA at the end of the first quarter which was 81 in the previous quarter. While we acknowledge the potential of HCA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
Yahoo
12 minutes ago
- Yahoo
Nootropics Depot's Tongkat Ali Declared Most Cost-Efficient and Potent in Industry, According to Independent Lab Tests
TEMPE, Ariz., Aug. 4, 2025 /PRNewswire/ -- New independent UPLC laboratory testing has confirmed that Nootropics Depot's Tongkat Ali extracts are the industry's leading choice for both cost efficiency and potency, dramatically outpacing seven major competitors. This robust data, generated by advanced Ultra-Performance Liquid Chromatography (UPLC), positions Nootropics Depot as the category benchmark for quality and transparency in the Tongkat Ali supplement market. Key findings highlight: Nootropics Depot's 10% eurycomanone extract delivers 18.0mg of active eurycomanone per dollar, a 3.3x cost advantage over the nearest competitor and up to 40x more value than premium-priced brands. Its 10% extract provides 10–12mg of lab-verified eurycomanone per 100mg dose, while competitors typically yield only 0.13–4mg per dose. Cost per mg of eurycomanone for Nootropics Depot's 10% extract is just $0.06, compared to $0.20 to $5.77 from competitors, leading to as much as 96x more active compounds per dollar spent. These results are detailed in a transparent, third-party report and set a new standard for evidence-based supplement selection. "We've always believed the best way to earn customer trust is transparency," said Paul Eftang, CEO of Nootropics Depot. "This independent lab data is validation for consumers. Not only are we delivering more of Tongkat Ali's active compounds, we're setting the bar for value, potency, and scientific rigor in an industry notorious for marketing hype." "Consumers deserve clear, standardized information so they can make meaningful health decisions — not just clever branding and proprietary blends," Eftang added. "We invite every brand to publish their own lab results. This is how the industry should operate." Nootropics Depot offers three main Tongkat Ali options: Tongkat Ali 10% Tablets: Highest potency, delivering up to 12mg eurycomanone per 100mg dose. Tongkat Ali 2% Capsules: Full-spectrum, balanced option with 4mg per 200mg dose. Eurycomax Optimized Stack: Combines two extraction methods with synergistic ingredients for broader hormonal support. Additionally, the company's transparent and published testing methods allow consumers to easily compare products, moving the supplement industry toward higher standards of honesty and efficacy. Nootropics Depot is a leading supplement company setting benchmark standards for quality and transparency in the industry. Founded in 2013, Nootropics Depot's mission has been to educate consumers on the science behind dietary supplements, and to advance the lab testing and quality control standards of the industry. Their stance is that consumers should be able to trust the products they buy, and that the brands selling those products have a duty to ensure they are using modern validated science. Nootropics Depot offers a wide range of high-quality cognitive enhancement and general health supplements. The company's commitment to quality and transparency is evident in their rigorous testing procedures, easily accessible Certificates of Analysis (COAs), and lab testing results available on every product page. In addition, they have formed a Scientific Advisory Board with board certified doctors, PhD researchers, and botanists to ensure that consumers can trust that scientific rigor is being upheld in everything they do. Nootropics Depot's newly redesigned website features a user-friendly interface, and includes an innovative quiz to help beginners find the right supplements for their needs. With partnerships with third-party labs, and collaboration with the Future Nutra Foundation, Nootropics Depot continues to push the boundaries of supplement quality and consumer education. For more information about Nootropics Depot's products and their commitment to transparency, visit Media ContactMichael PackmanMarketing ManagerNootropics Depotmichael@ View original content to download multimedia: SOURCE Nootropics Depot Sign in to access your portfolio
Yahoo
12 minutes ago
- Yahoo
BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology
BMI OrganBank is developing novel medical devices with potential to significantly reduce the waitlist for lifesaving organ transplants, beginning with kidneys FDA Breakthrough Device Designation secures expedited FDA engagement in advance of clinical studies planned for early next year WINSTON-SALEM, N.C., Aug. 4, 2025 /PRNewswire/ -- BMI OrganBank, a pioneering leader in organ assessment and preservation, proudly announces that its revolutionary organ preservation device has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation, granted for their kidney preservation device, underscores BMI OrganBank's commitment to advancing transformative technologies that will significantly improve outcomes for transplant patients. With current kidney perfusion technologies, which use cold storage temperatures, it is difficult to evaluate the function of kidneys before transplant. Furthermore, they are vulnerable to significant injury during the storage period before transplantation. As such, a large proportion of donated kidneys remain unused. BMI OrganBank's groundbreaking room temperature machine perfusion (RTMP) platform, developed in collaboration with leading transplant surgeons and academic medical centers, shows great promise to facilitate kidney quality assessment and extend preservation times. BMI OrganBank intends to increase the number of kidneys available for transplant and address stubbornly long kidney transplant waitlist times. A clinical study is planned for early next year. "We are incredibly honored to receive this significant designation from the FDA and look forward to working with them as we prepare for clinical studies" stated Carrie DiMarzio, Chief Executive Officer and Co-Founder. David A. Gerber, MD, abdominal transplant surgeon and Chief Medical Officer stated "We are energized by our promising preclinical data. The timing of this news is outstanding as my colleagues and I participate in the World Transplant Congress this week." About BMI OrganBank® BMI OrganBank specializes in developing transformative perfusion systems for organ and tissue evaluation and preservation. With facilities at the Innovation Quarter in Winston-Salem, NC, and Research Triangle Park, NC, the company is advancing multiple medical devices that use its patented and proprietary technologies. Its flagship product, the portable OrganBank kidney device, was co-developed with leading transplant surgeons and is set to begin clinical studies soon. Learn more at View original content to download multimedia: SOURCE BMI OrganBank Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
